Emma Walmsley’s elevation to the CEO role at GlaxoSmithKline PLC– the first female CEO of a big pharma company when she moves into the post later this year – is coming at a time when there’s a renewed focus on gender diversity in the biopharmaceutical C-suite. And it is an issue that isn’t going away.
After two years in a row of all-male roundtable discussions at Scrip’s annual biopharmaceutical executive roundtable at the J.P. Morgan...